<DOC>
	<DOCNO>NCT01423500</DOCNO>
	<brief_summary>With protocol ALL-SCT BFM international study group want - evaluate whether hematopoietic stem cell transplantation ( HSCT ) match family unrelated donor ( MD ) equivalent HSCT match sibling donor ( MSD ) . - evaluate efficacy hematopoietic stem cell transplantation ( HSCT ) mismatch family unrelated donor ( MMD ) compare HSCT match sibling donor match donor . - determine whether therapy carry accord main HSCT protocol recommendation . The standardisation treatment option HSCT different donor type aim achievement optimal comparison survival HSCT survival chemotherapy . - prospectively evaluate compare incidence acute chronic Graft-versus-Host-Disease ( GvHD ) HSCT match sibling donor ( MSD ) , match donor ( MD ) mismatch donor ( MMD ) .</brief_summary>
	<brief_title>ALL-SCT BFM International- HSCT Children Adolescents With ALL</brief_title>
	<detailed_description>Patients high risk relapse acute lymphoblastic leukaemia ( ALL ) bad prognosis compare patient ALL . For patient additional therapy approach require achieved remission multimodal chemotherapy . Allogeneic haematopoetic stem cell transplantation show promise result mainly due immunological antileukaemic control graft-versus-leukaemia effect treatment relate mortality morbidity remain serious problem .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>age time initial diagnosis relapse diagnosis , respectively equal 18 year indication allogeneic hematopoietic stem cell transplantation ( HSCT ) complete remission hematopoietic stem cell transplantation ( HSCT ) write consent parent ( legal guardian ) , necessary , minor patient via Informed Consent Form pregnancy secondary malignancy previous hematopoietic stem cell transplantation ( HSCT ) hematopoietic stem cell transplantation ( HSCT ) perform study participate centre . age time initial diagnosis relapse diagnosis , respectively 18 year indication allogeneic HSCT complete remission SCT write consent parent ( legal guardian ) , necessary , minor patient via Informed Consent Form pregnancy secondary malignancy previous HSCT HSCT perform study participate centre .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ALL</keyword>
	<keyword>HSCT</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
</DOC>